Calcium — a Neglected Key Factor in Arteriosclerosis. The Pathogenetic Role of Arterial Calcium Overload and Its Prevention by Calcium Antagonists

References

• Long E R. Development of our knowledge of arteriosclerosis. Cowdy's arteriosclerosis. A survey of the problem. First Edition, H T Blumenthal. Charles C Thomas Publ, Springfiedl/III USA 1933
   Google Scholar
• Anitschkow N, Chalatow S. Über experimented cholesterinsteatose und ihre Bedeutung für die Entstehung einiger pathologischer prozesse. Zentralbl f Allgemeine Pathol u Anat 1913; 14: 1–9
   Google Scholar
• Henry D P. Calcium channel blockers and atherosclerosis. J Cardiovasc Pharmacol 1990; 16((Suppl 1))S12–5
   PubMedGoogle Scholar
• Janke J, Hein B, Pachinger O, Leder O, Fleckenstein A. (1972) Hemmung arteriosklerotischer Gefässprozesse durch prophylaktische Behandlung mit MgCI2, KCI und organischen Ca++-Antagonisten (quantitative Studien mit 45Ca bei ratten). ascular Smooth Muscle, Verh Satel Symp XXV Internat Congr Physiol Wissenschatten, Tubingen, Juli, 1971, E Betz. Springer Verlag, Berlin-Heidelberg-New York, 71–2, V
   Google Scholar
• Fleckenstein A, Fleckenstein-Grün G. Cardiovascular protection by Ca antagonists. Eur Heart J 1980; 1: 15–21
   PubMedGoogle Scholar
• Fleckenstein A, Frey M, Leder O. (1983) Prevention by calcium antagonists of arterial calcinosis. Drug Development and Evaluation - New Calcium Antagonists - Recent Developments and Prospects, Diltiazem Workshop, Freiburg/Germany, May, 1982, A Fleckenstein, K Hashimoto, M Herrmann, A Schwartz, L Seipel. Gustav FischerVerlag, Stuttgart-New York, 15–31
   Google Scholar
• Fleckenstein A. Calcium Antagonism in Heart and Smooth Muscle - Experimental Facts and Therapeutic Prospects. John Wiley Publishing Company, New York-Chichester-Brisbane-Toronto-Singapore 1983
   Google Scholar
• Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G. Calcium, a neglected key factor in hypertension and arteriosclerosis. Experimental vasoprotection with calcium antagonists or ACE inhibitors. Hypertension: Pathophysiology, Diagnosis, and Management, J H Laragh, B M Brenner. Raven Press, New York 1990; 471–509
   Google Scholar
• Van Breemen C, Saida K. Cellular mechanisms regulating (Ca2+)i smooth muscle. Ann Rev Physiol 1989; 51: 315–9
   PubMed Web of Science ®Google Scholar
• Fleckenstein A. (1971) Specific inhibitors and promoters of calcium action in the excitation-contraction coupling of heart muscle and their role in the prevention or production of myocardial lesions. Calcium and the Heart. Proceed of the Meeting of the Europ Section of the Internat Study Group for Research in Cardiac Metabolism, London, Sept, 1970, P Harris, L Opie. Academic Press, London-New York, 135–88
   Google Scholar
• Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Ann Rev Pharmacol Toxicol 1977; 17: 149–66
   PubMed Web of Science ®Google Scholar
• Fleckenstein A. History of calcium antagonists. Calcium Channel Blocking Drugs: A Novel Intervention for the Treatment of Cardiac Disease, Monograph Nr 95 of the Amer Heart Association, A Schwartz, N Taira. Circ Res Part II, 1983; Vol 52: 3–16, Nr2
   Google Scholar
• Fleckenstein A, Kammermeier H, Döring H J, Freund H J, Grün G, Kienle A. Zum Wirkungsmechanismus neuartiger Koronardilatatoren mit Gleichzeitig Sauerstoff-einsparenden Myokard-Effekten, Prenylamin und Iproveratril. Z f Kreislaufforsch 1967; 56: 716–44, 839–58
   PubMedGoogle Scholar
• Grün G, Fleckenstein A. Die elektro-mechanische Entkoppelung der glatten Gefäßmuskulatur als Grundprinzip der Coronardilatation durch 4-(2′-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäure-dimethylester (Bay a 1040, Nifedipin). Arzneim Forsch (Drug Res) 1972; 22: 334–44
   PubMedGoogle Scholar
• Fleckenstein-Grün G, Fleckenstein A. Calcium antagonism, a basic principle in vasodilation. Calcium Antagonism in Cardiovascular Therapy: Experience with Verapamil, Internat Symp in Florence/Italy, Oct 1980, A Zanchetti, D M Krikler. Excerpta Medica, Amsterdam-Oxford-Princeton 1981; 30–8
   Google Scholar
• Fleckenstein A, Frey M, Fleckenstein-Grün G. Antihypertensive and arterial anticalcinotic effects of calcium antagonists. Am J Cardioi 1986; 57: 1D–10D
   PubMedGoogle Scholar
• Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G. Experimental basis of the long-term therapy of arterial hypertension with calcium antagonists. Am J Cardioi 1985; 56: 3H–14H
   PubMedGoogle Scholar
• Fleckenstein A, Fleckenstein-Grün G, Frey M, Zorn J. Future directions in the use of calcium antagonists. Am J Cardioi 1987; 59: 177B–87B
   Google Scholar
• Glossmann H, Ferry D R, Rombusch M. Molecular pharmacology of the calcium channel: evidence for subtypes, multiple drug receptor sites, channel subunits, and the development of radioiodinated 1,4-dihydropyridine calcium channel label, (125l) iodipine. J Cardiovasc Pharmacol 1984; 6: S608–21
   PubMed Web of Science ®Google Scholar
• Ferrante J, Triggle D J. Drug- and disease-induced regulation of voltage-dependent calcium channels. Pharmacol Rev 1990; 42: 29–44
   PubMed Web of Science ®Google Scholar
• Fleckenstein-Grün G, Frey M, Fleckenstein A. Calcium antagonists: Mechanisms and therapeutic uses. Trends in Pharmacological Sciences 1984; 5: 283–6
   Google Scholar
• Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G. The role of calcium in the pathogenesis of experimental arteriosclerosis. Trends in Pharmacological Sciences 1987; 8: 496–501
   Web of Science ®Google Scholar
• Fleckenstein A, Janke J, Döring H J, Pachinger O. Ca overload as the determinant factor in the production of catecholamine-induced myocardial lesions. Cardiomyopathies, Vol 2 of Recent Advances in Studies on Cardiac Structure and Metabolism, E Bajusz, G Rona. University Park Press, Baltimore 1973; 455–66
   Google Scholar
• Fleckenstein A, Janke J, Döring H J, Leder O. Myocardial fibre necrosis due to intracellular Ca overload - A new principle in cardiac pathophysiology. Myocardial Biology, Vol 4 of “Recent Advances in Studies on Cardiac Structure and Metabolism”, N S Dhalla. University Park Press, Baltimore 1974; 563–79
   Google Scholar
• Fleckenstein A, Janke J, Döring H J, Leder O. The key role of Ca in the production of noncoronarogenic myocardial necroses. Pathophysiology and Morphology of Myocardial Cell Alterations, Vol 6 of “Recent Advances in Studies on Cardiac Structure and Metabolism”, A Fleckenstein, G Rona. University Park Press, Baltimore-London-Tokyo 1975; 21–32
   Google Scholar
• Hansen Fischer J. Effects of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardioi 1990; 66: 779–85
   PubMedGoogle Scholar
• Kazda S. The calcium channel and vascular injury. The Calcium Channel; Structure, Functional Implications, M Morad, W Nayler, S Kazda, M Schramm. Springer Verlag, Berlin-Heidelberg-New York-London-Paris-Tokyo 1988; 11–4, Stresa/I, May 1988
   Google Scholar
• Dreyer E B, Kaiser P K, Offermann J T, Lipton S A. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science 1990; 248: 364–7
   PubMed Web of Science ®Google Scholar
• Fleckenstein A, Frey M, Fleckenstein-Grün G. (1983) Protection by calcium antagonists against experimental arterial calcinosis. Secondary Prevention of Coronary Heart Disease, Workshop of the Internat Soc and Federation of Cardiology, Titisee, Oct, 1983, K Pyörälä, E Rapaport, K König, G Schettler, C Diehm G. Thieme Verlag, Stuttgart-New York, 109–22
   Google Scholar
• Fleckenstein A, Frey M v., Witzleben H. (1983) Vascular calcium overload - a pathogenetic factor in arteriosclerosis and its neutralization by calcium antagonists. New Therapy of Ischemic Heart Disease and Hypertension, Proceed of the 5th Internat Adalat Symp, Berlin, May, 1982, M Kaltenbach, H N Neufeld. Excerpta Medica, Amsterdam-Oxford-Princeton, 36–52
   Google Scholar
• Lichtlen P R, Hugenholtz P G, Rafflenbeul W, Hecker H, Jost S, Nikutta P, Deckers J W. Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: Results of the INTACT Study (International Nifedipine Trial on Antiatherosclerotic Therapy). Cardiovasc Drugs and Therapy 1990; 4: 1047–68
   PubMed Web of Science ®Google Scholar
• Brown M S, Goldstein J L. How LDL receptors influence cholesterol and atherosclerosis. Sci Am 1984; 251(5)58–66
   PubMed Web of Science ®Google Scholar
• Fleckenstein A, Frey M, Thimm F, Fleckenstein-Grün G. Excessive mural calcium overload - A predominant causal factor in the development of stenosing coronary plaques in humans. Cardiovasc Drugs and Therapy 1990; 4: 1005–14
   PubMed Web of Science ®Google Scholar
• Fleckenstein-Grün G. Hypertension and arteriosclerosis: The role of calcium. Annals of Intern Med, (in press)
   Google Scholar
• Fleckenstein-Grün G, Frey M, Thimm F, Fleckenstein A. Differentiation between calcium-and cholesterol-dominated types of arteriosclerotic lesions. Antiarteriosclerotic aspects of calcium antagonists. J Cardiovasc Pharmacol, (in press)
   Google Scholar
• Moon J Y. Factors affecting arterial calcification associated with atherosclerosis. Atherosclerosis 1972; 16: 119–26
   PubMed Web of Science ®Google Scholar
• Blumenthal H T, Larving A J, Wheeler P A. Calcification of the media of the human aorta and its relation to intimal arteriosclerosis, ageing and disease. Am J Pathol 1944; 20: 655
   Google Scholar
• Weinstein D B, Heider J G. Antiatherogenic properties of calcium antagonists. Am J Cardioi 1987; 59: 163B–72B
   PubMed Web of Science ®Google Scholar
• Kramsch D M, Aspen A J, Rozlek J. Atherosclerosis: prevention by agents not affecting abnormal levels of blood lipids. Science 1981; 213: 1511–2
   PubMed Web of Science ®Google Scholar
• Herzenberg H. Studien über die Wirkungs weise des bestrahlten Ergosterins (Vigantol) und die Beziehungen der von ihm gesetzten Veränderungen zur Arteriosklerose. Beitr Path Anat 1929; 82: 27–56
   Google Scholar
• Eisenstein R, Zeruolis L. Vitamin-D-induced aortic calcification. Arch Path 1964; 77: 27–35
   PubMedGoogle Scholar
• Hass G M, Trueheart R E, Hemmens A. Experimental arteriosclerosis due to hypervitaminosis D. Am J Path 1960; 37: 521–39
   PubMed Web of Science ®Google Scholar
• Seydewitz V, Staubesand J. Calcifizierung der Arterienwand als Alternsprozess. Elektronenmikroskopische und biochemische Untersuchung am Modell der Vitamin D3-Überdosierung. Akt Gerontol 1983; 13: 114–8
   Google Scholar
• Triggle D J. Ca antagonists in atherosclerosis: a review and commentary. Cardiovasc Drug Res 1989; 6: 320–35
   Google Scholar
• Galle J, Bassenge E, Busse R. Oxidised low density lipoproteins potentiate vasoconstrictions to various agonists by direct interaction with vascular smooth muscle. Circ Res 1990; 66: 1287–1293
   PubMed Web of Science ®Google Scholar